Amgen confirmed Monday it will acquire rare disease giant Horizon Therapeutics for $26.4 billion.
And then there were two. Janssen (Johnson & Johnson) is no longer in the running to acquire rare disease player Horizon Therapeutics, the company announced Saturday.
Amgen is equipped with a broad and diverse product portfolio, commercial capabilities, and levers for delivering mid-single digit revenue growth over this decade.
While the economy expands and contracts, the biopharma industry follows, and many life science companies are announcing both layoffs and expansions.
Shares of ChemoCentryx are skyrocketing in premarket trading after the company announced it will be acquired by Amgen in a $4 billion deal that will bring Tavneos, a first-in-class treatment for ANCA-associated vasculitis, into the company’s portfolio.